Erratum

Avery Hughes^{1

2}, John K Marshall³, Myla E Moretti^{1

4}, Wendy J Ungar^{1

2}

Affiliations

¹ Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
² Program of Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
³ Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
⁴ Ontario Child Health Support Unit and the Clinical Trials Unit, The Hospital for Sick Children, Toronto, Ontario, Canada.

Published Erratum

Avery Hughes et al. J Can Assoc Gastroenterol. 2020.

. 2020 Mar 19;4(1):50.

doi: 10.1093/jcag/gwaa008. eCollection 2021 Feb.

Avery Hughes^{1

2}, John K Marshall³, Myla E Moretti^{1

4}, Wendy J Ungar^{1

2}

¹ Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
² Program of Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
³ Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
⁴ Ontario Child Health Support Unit and the Clinical Trials Unit, The Hospital for Sick Children, Toronto, Ontario, Canada.

Abstract

[This corrects the article DOI: 10.1093/jcag/gwz045.][This corrects the article DOI: 10.1093/jcag/gwz045.].

A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease.
Hughes A, Marshall JK, Moretti ME, Ungar WJ. Hughes A, et al. J Can Assoc Gastroenterol. 2020 Feb 11;4(1):48. doi: 10.1093/jcag/gwz045. eCollection 2021 Feb. J Can Assoc Gastroenterol. 2020. PMID: 33644677 Free PMC article.